ONCOGENE NRF2 AND ITS USE Russian patent published in 2013 - IPC C12Q1/68 A61K31/7088 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: method of prediction of response of a cancer patient to an agent that inhibits the expression, activity or biological way of mTOR comprises detecting the DNA or RNA coding the mutant protein NRF2 or detecting the mutant protein NRF2 in a tumor sample taken from a patient, and associating of the measured level of DNA or RNA encoding the mutant protein NRF2, or mutant protein NRF2, with the reaction of the cancer patient to the anticancer drug associated with mTOR. At that the higher level of NRF2, when compared to the patient with poor response to the anticancer drug associated with mTOR, indicates that the patient responds well to the anticancer drug associated with mTOR. The mutant NRF2 includes replacement of tryptophan 24 for cysteine or lysine, glutamine 26 for glutamic acid, isoleucine 28 for glycine, leucine 30 for phenylalanine, glycine 31 for alanine, glutamine 75 for histidine, aspartic acid 77 for valine or glycine, glutamic acid 79 for lysine, threonine 80 for lysine or proline and/or glutamic acid 82 for aspartic acid.

EFFECT: invention enables to optimise the conducting of anticancer therapy.

10 cl, 8 dwg, 2 tbl, 6 ex